-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 17th National Hematology Conference of the Chinese Medical Association was grandly opened
on September 23-25, 2022 at the National Convention and Exhibition Center in Shanghai.
With the theme of "Respect, Inheritance, Collaboration and Innovation", the conference covered basic research and clinical practice, and invited famous experts at home and abroad to discuss the latest progress
in the field of blood diseases.
During the meeting, Yimaitong invited experts to conduct interviews and reported
on cutting-edge developments.
This article summarizes past reports to help readers get the most out of
the conference.
At this conference, Yimaitong is honored to invite some experts in the field of blood to be interviewed and share the cutting-edge progress
related to blood diseases for us.
The relevant interview content is summarized below, click "Related Articles" to read related articles
.
- Review and prospect of hematology development in China
Professor Ma Jun of Harbin Institute of Hematology and Oncology explained the development process of China's hematological cancer field and the opportunities and challenges
of China's new drug innovative drug research and development.
For details, please stamp: 2022 CSH | Professor Ma Jun: Inheriting the century-old torch, innovating and intelligently creating the future: a review and prospect of the development of hematology in China
- lymphoma
Professor Qiu Lugui, Hospital of Hematology, Chinese Academy of Medical Sciences, shared his insights
on the current situation, the latest treatment progress and future development prospects in the field of lymphoma.
For details, please stamp: 2022 CSH | Professor Qiu Lugui: Grasp the foundation, pay attention to progress, China's lymphoma treatment prospects are broad
, Shanghai Jiao Tong University School of Medicine, Professor Zhao Weiyi interpreted the current situation and challenges in the field of DLBL, clinical treatment difficulties, the latest treatment progress and future development
.
For details, please stamp: 2022 CSH | Professor Zhao Weiyi: Talking about the present and future of DLBCL, I am grateful to remember every moment of the 17th National Hematology Conference of the Chinese Medical Association, Professor Zhang Huilai of Tianjin Medical University Cancer Hospital expressed his views on the treatment progress of DLBCL, "chemo-free" treatment and precision layered treatment.
For details, please stamp: 2022 CSH | Professor Zhang Huilai: "No chemotherapy" improves the quality of life of patients with indolent lymphoma, and precise stratification brings cure to R/R patients Professor Xu Wei of the First Affiliated Hospital of Nanjing Medical University explained the diagnosis, treatment and development status of CLL for us.
For details, please stamp: 2022 CSH | Professor Xu Wei: Exploration
of CLL diagnosis and treatment mode in the era of new drugsProfessor Cai Qingqing, Affiliated Cancer Hospital of Sun Yat-sen University, talked about the progress of basic and clinical research in the field of NK/T-cell lymphoma in the Affiliated Cancer Hospital of Sun Yat-sen University, for details, please poke: 2022 CSH| Professor Cai Qingqing: Progress in the treatment of NK/T-cell lymphoma
Professor Bai Ou from the First Hospital of Bethune of Jilin University explained the diagnosis and treatment of PTCL and the progress
of new drugs.
For details, please stamp: 2022 CSH | Professor Bai Ou: Looking for the precise treatment direction
of peripheral T-cell lymphoma Professor Yi Shuhua of the Hematology Hospital (Institute of Hematology) of the Chinese Academy of Medical Sciences explained the diagnosis, treatment and development status
of MCL for us.
For details, please stamp: 2022 CSH | Professor Yi Shuhua: We are on the way to solve the treatment dilemma of mantle cell lymphoma
- leukaemia
Professor Wang Jianxiang, Hospital of Hematology, Chinese Academy of Medical Sciences, shared with us the research progress in the field of ALL and the development prospects
of CD19 CAR-T therapy.
For details, please stamp: 2022 CSH | Professor Wang Jianxiang: The CD19 CAR-T Herquilenxel is poised in
r/r ALL Professor Chen Suning of the First Affiliated Hospital of Soochow University will explain the diagnosis and treatment of AML and the progress
of new drugs for us.
For details, please poke: 2022 CSH|Professor Chen Suning: New drugs and new technologies to promote the individualized diagnosis and treatment
of AML Professor Zou Dehui, Hematology Hospital, Chinese Academy of Medical Sciences, combined with clinical experience, introduced the application status of
CAR-T cell therapy to us.
For details, please stamp: 2022 CSH | Professor Zou Dehui: Application status of CAR-T cell therapy Professor Ji Chunyan of Qilu Hospital of Shandong University interpreted the current status and future development direction of precision treatment of
leukemia.
For details, please stamp: 2022 CSH | Hundreds of boats are racing against thousands of sails, and precision treatment is time! ——Professor Ji Chunyan talked about the precision treatment of leukemia Professor Wang Jin, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shared the current status of ALL diagnosis and treatment
and the prospect
for the future.
For details, please poke: 2022 CSH| Professor Wang Jin: CAR-T cell therapy is a double-edged sword, and the treatment prospects of new ALL drugs are considerable
- Multiple myeloma
Professor Niu Ting of West China Hospital of Sichuan University talked about the current situation and challenges in the field of MM, the difficulties of clinical treatment, the latest treatment progress and future development prospects
.
For details, please stamp: 2022 CSH | Professor Niu Ting: Based on the present and looking forward to the future, the development of multiple myeloma treatment in China Professor Sun Chunyan of the Union Medical College Affiliated to Tongji Medical College of Huazhong University of Science and Technology shared the application and research progress of CPCs detection in the clinical diagnosis and treatment of
MM.
For details, please poke: 2022 CSH| Professor Sun Chunyan: Application and research progress of circulating tumor plasma cell detection in the clinical diagnosis and treatment of multiple myeloma
- haemophilia
Professor Hu Yu of the Union Medical College Affiliated to Tongji Medical College of Huazhong University of Science and Technology reviewed the development of hemophilia in the past 40 years, shared the current diagnosis and treatment status, and made a future prospect.
For details, please stamp: 2022 CSH | Professor Hu Yu: Review of the 40-year development of hemophilia and future prospects02
Conference hotspots
Many experts in the field of hematology brought us wonderful academic reports
at the "17th National Hematology Academic Conference of the Chinese Medical Association".
The relevant conference hotspots are organized as follows, click "Related Articles" to read related articles
.
- lymphoma
Professor Wang Li, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, introduced the unmet diagnosis and treatment needs, treatment progress and precision treatment
of DLBCL with the topic of "Treatment Progress of Diffuse Large B-Cell Lymphoma (DLBCL)".
For details, please stamp: 2022 CSH | Professor Wang Li: Progress in the treatment
of diffuse large B-cell lymphoma In the special session on lymphocytic diseases on the afternoon of the 23rd and 24th, many experts gave special reports and discussions
on lymphocytic diseases.
For details of the special session on lymphocytic diseases on the afternoon of the 23rd, please poke: 2022 CSH big coffee gathered to talk about the way of accurate diagnosis and treatment, and the 17th National Hematology Academic Conference of the Chinese Medical Association - Lymphocytic Diseases Special Session was wonderful
.
For details of the lymphocytic disease session on the afternoon of the 24th, please poke: 2022 CSH | Lymphocytic diseases are a hundred schools of thought contending, and a hundred flowers are blooming! It has laid a solid foundation for the precise treatment of lymphoma in the future
- leukaemia
Professor Wei Hui, Hospital of Hematology, Chinese Academy of Medical Sciences, introduced the treatment progress of AML with FLT3 mutation in terms of prognostic characteristics, chemotherapy progress
, and targeted drugs with the topic of "Standardized diagnosis and treatment of FLT3 mutated AML".
For details, please stamp: 2022 CSH | Professor Wei Hui: Progress in the treatment of acute myeloid leukemia with FLT3 mutation Professor Xu Kailin of the Affiliated Hospital of Xuzhou Medical University introduced the application status of CAR-T cell therapy in R/R B-ALL with the topic of "CAR-T and hematopoietic stem cell transplantation for the treatment
of B-ALL".
For details, please stamp: 2022 CSH | Professor Xu Kailin: The strong combination of CAR-T and allo-HSCT has benefited B-ALL patients more
, and Professor Wang Ying of the Hematology Hospital of the Chinese Academy of Medical Sciences shared the progress of R/R B-ALL CAR-T treatment for
us at the meeting.
For details, please poke: 2022 CSHProfessor Wang Ying: A new breakthrough in CAR-T therapy, Hekilensai injection is expected to break the bottleneck of r/r B-ALL treatment, Tianjin First Central Hospital Professor Zhao Mingfeng gave a lecture on the current status of CAR-T therapy in the field of AML and the development of each target with the topic of "Clinical Application Status of CAR-T Cell Therapy for AML and Research on New Target CD312"
。 For details, please stamp: 2022 CSH | Professor Zhao Mingfeng: Research progress of CAR-T cells in the treatment of acute myeloid leukemia, Professor Xia Linghui, Department of Hematology, Tongji Medical College Affiliated Union Hospital, Huazhong University of Science and Technology, introduced the current status and prevention strategies of recurrence after allo-HSCT with the topic of "Progress in the prevention and control of recurrence after allogeneic hematopoietic stem cell transplantation in high-risk AML/MDS patients".
For details, please stamp: 2022 CSH | Professor Xia Linghui: Progress in the prevention and treatment of recurrence after allogeneic hematopoietic stem cell transplantation in high-risk AML/MDS patients
- other
Professor Han Weidong of the General Hospital of the Chinese People's Liberation Army introduced the development and current status
of CAR-T therapy in the field of hematological cancer treatment with the topic of "Review and prospect of CAR-T cells in the treatment of hematological malignancies".
For details, please poke: 2022 CSH|Professor Han Weidong: Review and prospect of CAR-T cell therapy for hematological malignancies Professor Jiang Erlie of Hematology Hospital of Chinese Academy of Medical Sciences introduced the development and current status of acute graft-versus-host disease with the topic of "Progress in Prevention and Treatment of Acute Graft-versus-Host Disease".
For details, please poke: 2022 CSH|Professor Jiang Erlie: Progress in the prevention and treatment of acute graft-versus-host disease, a number of academic experts explored the latest research progress of HSCT.
For details, please stamp: 2022 CSH | Focusing on the frontier of transplantation and exploring the way of diagnosis and treatment, the 17th National Conference of Hematology of the Chinese Medical Association - Transplantation Frontier Forum is wonderful!
A number of academic experts shared their topics and interpreted papers to discuss the cutting-edge progress
of hematopoietic stem cell transplantation.
For details, please stamp: 2022 CSH | Passing on the progress of transplantation and interpreting academic frontiers, the 17th National Hematology Academic Conference of the Chinese Medical Association - Hematopoietic Stem Cell Transplantation Group Forum was successfully concluded
and sorted: Wenting Typesetting: Wenting Executive: moly
Disclaimer: This platform aims to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with it
as soon as possible.
Poke "Read Original" to see more
